From which country are you accessing the website?

You will be redirected to the related website.

We use cookies to give you a better experience of our website. By continuing we will assume that you are ok with receiving cookies. The information stored in the cookie is used to hide this screen for further visits. If you delete your cookies or the specific cookie for this website you will be redirected to this page again.

» Germany

» Other


We use cookies on our website. A cookie is a small text file sent to your computer when you visit our website; it helps the website to identify and recognize your browser as a visitor to our page.

This information helps us optimize our content and make surfing on our site more convenient for you. In some cases, cookies are also used to make specific information about our products available on websites of other providers. This is why we also work with external service companies which use the information obtained from cookies exclusively for this purpose.
The information obtained from cookies is not used for any further purpose.
Cookies are completely harmless for your computer: beyond that, from a technical standpoint it is not at all possible to use cookies to read personal data from your computer.
You can adjust the settings on your browser so that you are notified whenever a server wants to send you a cookie. You can accept or reject cookies; you can also completely block them. Further information is available in the help function of your browser.

Google Analytics

This website uses Google Analytics, a web analytics service provided by Google, Inc. (“Google”). Google Analytics uses “cookies”, which are text files placed on your computer to help the website analyze how users use the site. The information generated by the cookie about your use of the website (including your IP address) will be transmitted to and stored by Google on servers in the United States. In case of activation of the IP anonymization, Google will truncate/anonymize the last octet of the IP address for Member States of the European Union as well as for other parties to the Agreement on the European Economic Area. Only in exceptional cases is the full IP address sent to and shortened by Google servers in the USA. On behalf of the website provider, Google will use this information for the purpose of evaluating your use of the website, compiling reports on website activity for website operators and providing other services relating to website activity and Internet usage to the website provider. Google will not associate your IP address with any other data held by Google. You may refuse the use of cookies by selecting the appropriate settings on your browser. However, please note that if you do this, you may not be able to use the full functionality of this website. Furthermore you can prevent Google’s collection and use of data (cookies and IP address) by downloading and installing the browser plug-in available under

In light of the discussion about the use of Analysetools and complete IP addresses, we wish to state that this website works with Google Analytics and the "_anonymizeIp()" function; consequently, it only processes partial IP addresses so as to rule out identifying information.

You can refuse the use of Google Analytics by clicking on the following link. An opt-out cookie will be set on the computer, which prevents the future collection of your data when visiting this website: Disable Google Analytics.*

Further information concerning the terms and conditions of use and data privacy can be found at
or at*


News Header Image


Clinical study confirms efficacy and safety of EPs® 7630 in children and adolescents

Respiratory tract infections are the most common reason why children are taken to the doctor. Taking into account that infections such as acute bronchitis are caused by viruses around 90% of the time, antibiotics are still prescribed too often — especially given the fact that antibiotics are not effective in viruses.

On the other hand, children and adolescents are frequently treated using medicines without proven efficacy and, in particular, without proven tolerability..

This is not at all the case for EPs® 7630: In various studies, including one from 2012*, scientists have confirmed that EPs® helps patients to recover more quickly while being safe and well tolerated.

The recent investigation included 200 children and adolescents between 1 and 18 years of age who had acute bronchitis including typical complaints such as cough and difficulties in breathing. Half of the participants were given placebos whereas the other half received the active substance EPs® 7630. The result of this trial: Patients in the EPs® group showed a significantly faster improvement of the symptoms. After seven days of treatment with EPs®, nearly 60% of the children could return to kindergarten or school, whereas this was the case for only 17% within the placebo group. This study demonstrates again the clinically proven efficacy and safety of EPs® — particularly in children and adolescents.

*Kamin et al, Pediatrics International 2012; 54; 219 – 226

Local brands


English: Please note that you are leaving the website.
This link will take you to a website to which our Legal notice does not apply. Dr. Willmar Schwabe GmbH & Co KG is not accountable for this content.